Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN9 Biologics Sequence Review Report 2026: Claudin-9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN9 Biologics Sequence Review Report 2026: Claudin-9 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN7 Biologics Sequence Review Report 2026: Claudin-7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN7 Biologics Sequence Review Report 2026: Claudin-7 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN8 Biologics Sequence Review Report 2026: Claudin-8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN8 Biologics Sequence Review Report 2026: Claudin-8 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN1 Biologics Sequence Review Report 2026: Claudin-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN1 Biologics Sequence Review Report 2026: Claudin-1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN2 Biologics Sequence Review Report 2026: Claudin-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN2 Biologics Sequence Review Report 2026: Claudin-2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN5 Biologics Sequence Review Report 2026: Claudin-5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN5 Biologics Sequence Review Report 2026: Claudin-5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BACE2 Biologics Sequence Review Report 2026: Beta-secretase 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BACE2 Biologics Sequence Review Report 2026: Beta-secretase 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BACE1 Biologics Sequence Review Report 2026: Beta-secretase 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BACE1 Biologics Sequence Review Report 2026: Beta-secretase 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL11 Biologics Sequence Review Report 2026: Eotaxin Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL11 Biologics Sequence Review Report 2026: Eotaxin Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CCL11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ALK Biologics Sequence Review Report 2026: ALK tyrosine kinase receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ALK Biologics Sequence Review Report 2026: ALK tyrosine kinase receptor Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ALK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ADGRF5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ADGRF5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ADGRF5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →